MedPath

GSK's Meningococcal Group B Vaccine Approved in the Philippines

• GSK's Meningococcal Group B Vaccine receives FDA approval in the Philippines, marking the first vaccine available in the country for this serogroup. • The vaccine is approved for individuals aged two months and older to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B. • Serogroup B is a leading cause of IMD in the Philippines, accounting for 68% of cases between 2017 and 2018, according to a study. • The approval provides a crucial tool to prevent meningitis B and its severe consequences, with the vaccine already licensed in over 40 countries.

The Philippine Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Meningococcal Group B Vaccine, making it the first vaccine available in the country to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B. This approval marks a significant advancement in public health, offering protection to individuals aged two months and older. Meningococcal disease is a serious and potentially life-threatening infection, and until now, no vaccine was available in the Philippines for serogroup B.

Serogroup B Prevalence and Impact

According to the National Center for Biotechnology Information (NCBI), meningococcal disease is endemic in the Philippines, with approximately 100 cases reported annually. Serogroup B is a leading cause of IMD both globally and locally. A paper published in Microbiology Australia indicated that serogroup B accounted for 68% of invasive meningococcal disease cases in the Philippines between 2017 and 2018.
IMD can lead to meningitis, an inflammation of the membranes surrounding the brain and spinal cord, and meningococcal sepsis, where bacteria enter the bloodstream. These conditions require immediate medical intervention to avert irreversible consequences such as permanent hearing loss, vision impairment, and cognitive difficulties. Infants and children are particularly vulnerable to the disease.

Expert Commentary

Dr. Giovell P. Barangan, country medical director of GSK Philippines, emphasized the severity of IMD, stating, "IMD can lead to severe illness, long-term complications, or even death, often affecting patients in ways that can alter their lives forever." He further added, "The availability of this vaccine in the Philippines represents a significant step in protecting families and their loved ones from the life-threatening outcomes of IMD."

Global Availability

GSK's Meningococcal Group B Vaccine has already been licensed in over 40 countries, including member states of the European Union, Australia, Canada, New Zealand, and the United States. This widespread availability underscores the vaccine's established safety and efficacy profile.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves New Vial Sizes of Niktimvo for Chronic Graft-Versus-Host Disease

The FDA has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for chronic graft-versus-host disease (GVHD) after two prior systemic therapies.
Niktimvo is the first FDA-approved treatment targeting CSF-1R to reduce inflammation and fibrosis in chronic GVHD, offering a novel approach for patients.

GSK's Shingrix Prefilled Syringe Under Review by FDA and EMA for Shingles Prevention

The FDA and EMA are reviewing GSK's application for a Shingrix prefilled syringe, potentially streamlining vaccine administration.
The new syringe formulation aims to simplify the vaccination process by removing the need for reconstitution.

FDA Awards Breakthrough Status to Pfizer's Group B Strep Vaccine

The FDA has granted breakthrough status to Pfizer's Group B Streptococcus (GBS) vaccine, based on promising phase 2 data. This vaccine aims to protect newborns and young infants from invasive infections by immunizing expectant mothers. GBS is a leading cause of life-threatening infections in newborns, and the breakthrough status could expedite the vaccine's regulatory review process.

SK bioscience's mRNA Japanese Encephalitis Vaccine Candidate, GBP560, Approved for Clinical Trials in Australia

SK bioscience has received approval to begin Phase I/II clinical trials in Australia for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.
The trials will assess the safety and immunogenicity of GBP560 in 402 healthy adult subjects, with interim results expected by 2026.

GSK's Nucala (Mepolizumab) Shows Promise in COPD Treatment, Regulatory Submissions Underway

GSK's Nucala (mepolizumab) demonstrates a clinically meaningful reduction in moderate/severe exacerbations in COPD patients with an eosinophilic phenotype.
The MATINEE Phase III trial supports regulatory submissions for Nucala as an add-on maintenance treatment for COPD, potentially the first monthly biologic for this condition.

GSK's Penmenvy Approved by FDA for Meningococcal Disease Prevention in Adolescents and Young Adults

The FDA has approved GSK's Penmenvy vaccine for individuals aged 10-25, targeting five major serogroups of Neisseria meningitidis.
Penmenvy combines antigenic components from GSK's Bexsero and Menveo vaccines, offering broader protection against invasive meningococcal disease (IMD).

GSK's Single-Vial, Fully Liquid Menveo Receives Positive CHMP Opinion for Meningococcal Disease Prevention

The European Medicines Agency's CHMP has recommended GSK's single-vial, fully liquid Menveo for active immunization against invasive meningococcal disease (IMD).
If approved, the new formulation will simplify vaccine administration by eliminating the need for reconstitution before use in individuals aged two years and older.

FDA Grants Fast Track Designation to Glycomine's GLM101 for PMM2-CDG Treatment

The FDA has granted Fast Track designation to Glycomine's GLM101, a mannose-1-phosphate replacement therapy, for treating phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
GLM101 is currently in a Phase 2 clinical study involving adult and adolescent patients, with plans to expand enrollment to pediatric patients aged two years and older.

Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis

Nipocalimab, combined with standard of care, demonstrates sustained disease control in adolescents (12-17 years) with generalized myasthenia gravis (gMG) over 24 weeks.
The Phase 2/3 Vibrance-MG study shows a significant reduction in immunoglobulin G (IgG) levels and improvements in MG-ADL and QMG scores.

FDA Approves Shingrix for Shingles Prevention in Immunocompromised Adults

The US Food and Drug Administration (FDA) has approved Shingrix, a non-live, recombinant subunit vaccine, for the prevention of shingles in adults aged 18 years and older who are at increased risk due to immunodeficiency or immunosuppression. This approval expands the vaccine's use beyond its initial approval for adults 50 years and older, offering protection to a broader population at risk of shingles and its complications.

Reference News

[1]
GSK gets FDA approval for meningococcal vaccine - Manila Standard
manilastandard.net · Oct 15, 2024

GSK's Meningococcal Group B Vaccine, first in the Philippines, approved by FDA to prevent invasive meningococcal disease...

[2]
Meningococcal group B vaccine receives Philippine FDA approval - BusinessWorld Online
bworldonline.com · Oct 16, 2024

Philippine FDA approved GSK's Meningococcal Group B Vaccine on Oct 15 for individuals aged 2 months or older, addressing...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy